INSUBCONTINENT EXCLUSIVE:
BEIJING: Phase 3 trials of a Sinopharm coronavirus vaccine found it was 79% effective, the Chinese pharma giant said Wednesday, lower than
rival jabs developed by Pfizer-BioNTech and Moderna but a potential breakthrough in the battle to stem the pandemic in Asia.
ImageCredits: Bangkok Post
